Syncromune®
Biotechnology Research • 
Fort Lauderdale, Florida, United States • 21-50 Employees
Company overview
| Headquarters | Fort Lauderdale, Florida, United States |
| Phone number | +15187966110 |
| Website | |
| NAICS | 541714 |
| Keywords | Lung Cancer, Prostate Cancer, Cervical Cancer, Breast Cancer, Immunotherapy, Bladder Cancer, Head And Neck Cancer, Cancer Vaccine, Mcrpc, Renal Cancer, Intratumoral Immunotherapy, Combination Cancer Therapy, Metastatic Solid Tumors, Multi-Target Biologic Drug, In Situ Cancer Vaccine |
| Founded | 2020 |
| Employees | 21-50 |
| Socials |
Key Contacts at Syncromune®
Michael S Battersby
Sr. Director: Quality Operations
John Shea
Sr. Director, Clinical Operations
Syncromune® Email Formats
Syncromune® uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@syncromune.com), used 73.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@syncromune.com | 73.9% |
{first name}{last name} | johndoe@syncromune.com | 26.1% |
About Syncromune®
LEGION-100 Trial for Metastatic Prostate Cancer is Now Enrolling - Learn More: www.legion100trial.com Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class platform immunotherapy designed to address major unmet needs and treatment challenges of incurable metastatic solid tumor cancers. SYNC-T is an in situ personalized cancer therapy engineered to synchronize the location of three components critical to T cell activation and an anti-tumor immune response: tumor antigens, immune cells, and our multi-target biologic drug. SYNC-T features a novel proprietary device delivery system that is optimized for combination drug/device immunotherapy. First, the system lyses a portion of a target tumor to rupture tumor cells and release tumor antigens into the tumor microenvironment (TME) that help to activate the immune system. Next, the delivery system facilitates the infusion of our proprietary multi-target biologic drug directly into the tumor. This synchronization of location approach is designed to unite the three critical components together in the TME and lymphatics where the immune system optimally functions. The combination therapy targets numerous mechanisms of cancer, promoting in situ immune activation while also battling immune suppression and minimizing systemic drug exposure. The goal is to activate T cells, empowering the immune system to recognize and attack the patient’s cancer throughout the body and defend with immune memory. Our lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer (mCRPC), is being evaluated in a U.S., multicenter, Phase 2a trial. For more information, please visit www.legion100trial.com.
Syncromune® revenue & valuation
| Annual revenue | $3,165,535 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $10,200,000 |
| Total funding | $172,600,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Syncromune® has 18 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Syncromune®'s funding history, including investment rounds, total capital raised, and key backers.
Syncromune® Tech Stack
Discover the technologies and tools that power Syncromune®'s digital infrastructure, from frameworks to analytics platforms.
WordPress plugins
JavaScript libraries
Video players
Performance
JavaScript libraries
Page builders
JavaScript libraries
CDN
Translation
SEO
Font scripts
India
Germany
France
ChinaFrequently asked questions
4.8
40,000 users
